Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Fever of Unknown Origin D005335 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Conjunctivitis, Inclusion D003235 4 associated lipids
Typhus, Endemic Flea-Borne D014437 3 associated lipids
Urethral Diseases D014522 4 associated lipids
Chlamydiaceae Infections D002694 2 associated lipids
Lymphogranuloma Venereum D008219 4 associated lipids
Superinfection D015163 3 associated lipids
Otitis Media, Suppurative D010035 4 associated lipids
Serum Sickness D012713 7 associated lipids
Bites, Human D001734 2 associated lipids
Rickettsia Infections D012282 5 associated lipids
Pharyngeal Diseases D010608 4 associated lipids
Granuloma Inguinale D006100 2 associated lipids
Erythema Chronicum Migrans D015787 3 associated lipids
Elephantiasis, Filarial D004605 4 associated lipids
Hearing Loss, Conductive D006314 2 associated lipids
Granuloma, Pyogenic D017789 2 associated lipids
Bartonella Infections D001474 3 associated lipids
Ethmoid Sinusitis D015521 2 associated lipids
Otorhinolaryngologic Diseases D010038 3 associated lipids
Dry Socket D004368 3 associated lipids
Nasopharyngeal Diseases D009302 2 associated lipids
Furunculosis D005667 2 associated lipids
Elephantiasis D004604 2 associated lipids
Lymphangitis D008205 4 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Herpes Genitalis D006558 2 associated lipids
Pericoronitis D010497 2 associated lipids
Tuberculosis, Urogenital D014401 2 associated lipids
Moraxellaceae Infections D045828 3 associated lipids
Abdominal Abscess D018784 2 associated lipids
Pyloric Stenosis, Hypertrophic D046248 2 associated lipids
Hoarseness D006685 2 associated lipids
Scrub Typhus D012612 3 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Pneumocystis Infections D016720 1 associated lipids
Frontal Sinusitis D015522 1 associated lipids
Toxoplasmosis, Ocular D014126 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Leishmaniasis, Mucocutaneous D007897 1 associated lipids
Trichiasis D058457 1 associated lipids
Paratyphoid Fever D010284 1 associated lipids
Ectodermal Dysplasia D004476 1 associated lipids
Tooth Erosion D014077 2 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Odenholt-Tornqvist I et al. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. 1995 Antimicrob. Agents Chemother. pmid:7695310
Malinverni R et al. Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. 1995 Antimicrob. Agents Chemother. pmid:7695327
Nalca Y et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. 2006 Antimicrob. Agents Chemother. pmid:16641435
Asgrimsson V et al. Novel effects of azithromycin on tight junction proteins in human airway epithelia. 2006 Antimicrob. Agents Chemother. pmid:16641453
Chave JP et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. 1992 Antimicrob. Agents Chemother. pmid:1324635
Derouin F et al. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1324642
Vallée E et al. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. 1992 Antimicrob. Agents Chemother. pmid:1324644
Merchan LM et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. 2015 Antimicrob. Agents Chemother. pmid:25385115
Mertens JC et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. 1992 Antimicrob. Agents Chemother. pmid:1324645
Pajukanta R et al. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. 1992 Antimicrob. Agents Chemother. pmid:1329617
Bonnet M and Van der Auwera P In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. 1992 Antimicrob. Agents Chemother. pmid:1329619
Koletar SL et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 Antimicrob. Agents Chemother. pmid:10582873
Nicolau DP et al. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. 1999 Antimicrob. Agents Chemother. pmid:10582906
Dagan R et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. 2000 Antimicrob. Agents Chemother. pmid:10602721
McGannon CM et al. Different classes of antibiotics differentially influence shiga toxin production. 2010 Antimicrob. Agents Chemother. pmid:20585113
Koetsveld J et al. Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents. 2017 Antimicrob. Agents Chemother. pmid:28674060
Clark C et al. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. 2002 Antimicrob. Agents Chemother. pmid:12183253
Ng LK et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. 2002 Antimicrob. Agents Chemother. pmid:12183262
Matsui H et al. Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. 2005 Antimicrob. Agents Chemother. pmid:16048953
Prunier AL et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. 2002 Antimicrob. Agents Chemother. pmid:12183270
Collins SA et al. Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. 2017 Antimicrob. Agents Chemother. pmid:27919896
Galarza PG et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. 2010 Antimicrob. Agents Chemother. pmid:20123998
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Carryn S et al. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. 2002 Antimicrob. Agents Chemother. pmid:12069960
Babl FE et al. Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. 2002 Antimicrob. Agents Chemother. pmid:12069974
Tissi L et al. In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. 1995 Antimicrob. Agents Chemother. pmid:8540695
Sahm DF et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. 2001 Antimicrob. Agents Chemother. pmid:11257013
Koirala KD et al. Highly resistant Salmonella enterica serovar Typhi with a novel gyrA mutation raises questions about the long-term efficacy of older fluoroquinolones for treating typhoid fever. 2012 Antimicrob. Agents Chemother. pmid:22371897
Oh YK et al. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. 1995 Antimicrob. Agents Chemother. pmid:8540724
Erhardt W et al. Establishing criteria for assessment of efficacy of antimicrobial agents in acute otitis media. 2000 Antimicrob. Agents Chemother. pmid:11012390
Cigana C et al. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. 2007 Antimicrob. Agents Chemother. pmid:17210769
Farrell DJ et al. Results from the Solithromycin International Surveillance Program (2014). 2016 Antimicrob. Agents Chemother. pmid:27044551
Nagai K et al. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries. 2002 Antimicrob. Agents Chemother. pmid:11796375
Sugimura M et al. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. 2008 Antimicrob. Agents Chemother. pmid:18676884
Liu P et al. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. 2011 Antimicrob. Agents Chemother. pmid:21859932
Sjölund-Karlsson M et al. Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. 2011 Antimicrob. Agents Chemother. pmid:21690279
Cynamon MH et al. Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7979270
Klemens SP and Cynamon MH Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7979271
Schwab JC et al. Localization of azithromycin in Toxoplasma gondii-infected cells. 1994 Antimicrob. Agents Chemother. pmid:7979295
Ramya TN et al. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. 2007 Antimicrob. Agents Chemother. pmid:17060533
Shima K et al. Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia. 2013 Antimicrob. Agents Chemother. pmid:23478971
Bermudez LE et al. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. 1994 Antimicrob. Agents Chemother. pmid:8067766
Goodman CD et al. Chemobiosynthesis of new antimalarial macrolides. 2013 Antimicrob. Agents Chemother. pmid:23208707
Kim MK et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. 2002 Antimicrob. Agents Chemother. pmid:12234843
Ma Q et al. A Waterborne Outbreak of Shigella sonnei with Resistance to Azithromycin and Third-Generation Cephalosporins in China in 2015. 2017 Antimicrob. Agents Chemother. pmid:28373192
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Welsh L et al. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8787907
Schroeck JL et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. 2015 Antimicrob. Agents Chemother. pmid:25870064
Waites KB et al. In vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas. 2015 Antimicrob. Agents Chemother. pmid:25824220
Edelstein PH et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. 2001 Antimicrob. Agents Chemother. pmid:11451675